Showing 3621-3630 of 5646 results for "".
- Prevent Blindness Provides Free Glaucoma Resources to Patients, Care Partners, and Professionalshttps://modernod.com/news/prevent-blindness-provides-free-glaucoma-resources-to-patients-care-partners-and-professionals/2482593/As part of January’s National Glaucoma Awareness Month, the non-profit Prevent Blindness is offering free educational resources to patients, care partners, and professionals. The resources include downloadable
- Opus Genetics Receives FDA Agreement Under SPA for Phase 3 Trial of APX3330 in DRhttps://modernod.com/news/opus-genetics-receives-fda-agreement-under-spa-for-phase-3-trial-of-apx3330-in-diabetic-retinopathy/2482587/Opus Genetics announced it has reached agreement with the FDA on a Special Protocol Assessment (SPA) for a phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR).
- Vabysmo Prefilled Syringe (PFS) Approved in the EUhttps://modernod.com/news/vabysmo-prefilled-syringe-pfs-approved-in-the-eu-for-three-retinal-conditions/2482582/The European Medicines Agency (EMA) has approved Roche's Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion
- Viridian Announces Topline Results from Veligrotug Phase 3 Trial in Patients with Chronic TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-veligrotug-phase-3-trial-in-patients-with-chronic-thyroid-eye-disease/2482580/Viridian Therapeutics announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). “We are extremely
- CellViva Appoints Three Ophthalmology Leaders to Board of Directorshttps://modernod.com/news/cellviva-appoints-three-ophthalmology-leaders-to-board-of-directors/2482577/CellViva, a biopharmaceutical company developing anti-vascular endothelial growth factor—anti-VEGF—therapy for pterygium, announced the appointment of three leaders in ophthalmology to its Board of Directors. According to CellViva, the new directors are: Ad
- Bausch + Lomb Acquires Elios Vision to Bolster Glaucoma Surgical Portfoliohttps://modernod.com/news/bausch-lomb-acquires-elios-vision-to-bolster-glaucoma-surgical-portfolio/2482575/Bausch + Lomb announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, a minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. Financial terms of the deal were not disclosed. According to B+
- UC Irvine Scientists Find DNA Damage is Key Factor in AMDhttps://modernod.com/news/uc-irvine-scientists-find-dna-damage-is-key-factor-in-amd/2482569/Accumulated DNA damage in the retina is a key contributor to age-related macular degeneration (AMD) and that targeting specific retinal cell types may lead to treatments that slow or stop progression, according to a research team co-led by the University of California, Irvine. The
- New “Eying the Future" School Program Seeks to Fuel Student Interest in Optometryhttps://modernod.com/news/new-eying-the-future-school-program-seeks-to-fuel-student-interest-in-optometry/2482568/Latinos en Optometry has partnered with Transitions Optical to launch "Eying the Future," a free in-school educational program specifically designed to inspire middle and high school students in Latino communities to consider
- Outlook Therapeutics Receives NICE Recommendation of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-receives-nice-recommendation-for-lytenava-as-a-treatment-for-wet-amd/2482567/The UK’s National Institute for Health and Care Excellence (NICE) has recommended Lytenava (bevacizumab gamma) as an option for the treatment of wet AMD in adults. This marks the first positive reimbursement decision for Lytenava worldwide and supports its commercializat
- Galimedix Begins Phase 1 Clinical Trial of Oral GAL-101 for Neuroprotective Treatmenthttps://modernod.com/news/galimedix-therapeutics-begins-phase-1-clinical-trial-of-oral-gal-101-for-neuroprotective-treatment/2482565/Galimedix Therapeutics announced the first volunteers have been dosed in the company’s phase 1 study of oral GAL-101, an amyloid beta (Aβ) aggregation modulator. This trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses